TransMedics Group, Inc. (TMDX) income statement
TMDXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3029% below fair value
$96.43+2.52 (+2.68%)
Close on Nov 18, 2026Market cap $3.34BP/E 25.0Yield 0.00%
TransMedics Group, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 58.7%
- Operating margin
- 12.2%
- Net margin
- 22.7%
- Return on equity, FY2025
- 54.2%
Financial strength
- Current ratio
- 6.62
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 480.9%
Valuation
- P/E ratio
- 25.0
- Price to sales
- 5.00
- Price to book
- 6.45
- Dividend yield
- 0.00%
See a number that looks wrong?